“We bring patients and professionals closer to 4P medicine: personalised, predictive, preventive and participative”
Genetic analysis is a tool for early diagnosis and identification of markers in order to target treatment more effectively
World Cancer Day, a disease that one in two men and one in three women will suffer from in their lifetime, was held on 4th February. It is promoted by the World Health Organisation, the International Agency for Research on Cancer (IARC) and the Union for International Cancer Control (UICC). The aim is to raise awareness and mobilise society to make progress in the prevention and control of this disease.
TECNALIA joins the collective effort in this field, contributing technology, knowledge and genetic analysis tools that enable new trends in precision medicine to be adopted. They also enable appropriate care, therapeutic and follow-up strategies to be adopted for each patient.
According to annual estimates by the Spanish Society of Medical Oncology (SEOM), the number of cancer diagnoses in 2023 is expected to reach 279,260 new cases, with cancer of the colon and rectum, breast, lung, prostate and bladder being the most frequently diagnosed.
Although in most cases, the onset of the disease is due to the interaction of multiple environmental factors, cancer is a genetic disease, which occurs as a result of the accumulation of multiple alterations in the genome of the cells that will give rise to the tumour.
Precision medicine
This is where the concept of precision medicine arises and is best applied; understood (from a genetic point of view) as the capacity to study and identify the genetic characteristics of each individual tumour in order to apply therapeutic, detection, monitoring and prevention strategies specific to each individual patient, and which respond to the characteristics of the tumour that affects them.
The development of genetic analysis technologies, which has taken place in recent years, has enabled genetic tests that allow for early diagnosis, monitoring and prevention of the disease to emerge and be implemented in clinical practice, favouring the adoption of specific therapeutic strategies in early stages of the disease and thus increasing the likelihood of cure
Development of genetic analysis technologies
TECNALIA specialises in the analysis of panels of specific genes associated with the most common hereditary tumour syndromes in the population, through the use of massive sequencing (NGS) and capillary sequencing (Sanger) technologies.
Our main objective is to bring 4P (personalised, predictive, preventive and participatory) medicine closer to patients and professionals, for which it is necessary to make genetic analysis and diagnosis accessible to both doctors and patients.
